Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib Candela Moliz, Eduardo Gutiérrez, Teresa Cavero, Beatriz Redondo, Manuel Praga

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3 Emanuel Ferreira, Nuno Oliveira, Maria Marques, Luís Francisco, Ana Santos, Armando Carreira, Mário Campos

Late onset of de novo atypical hemolytic–uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab Francisco Javier Juega-Mariño, Neus Sala, Dolores López, Laura Cañas, Josep Bonet, Ricardo Lauzurica